title: Supportive care including growth factors in myelodysplastic syndromes.
abstract: In spite of recent advances in the treatment of myelodysplastic syndromes (MDS), supportive care remains a very important part of the therapy. Red blood cells transfusions are the most important component of this supportive care. They transiently relieve anemia symptoms and alleviate their effects on quality of life and daily functioning. Platelet transfusion therapy is less frequently needed, at least in low-risk MDS. Dealing with an increased risk of infections linked to neutropenia, mainly by broad spectrum antibiotics, is also needed, more often in advanced stages of [dict: MDS] or when the MDS evolves to acute myeloid leukemia. Chronic red blood cell transfusions expose patients to various side-effects, including blood components intolerance reactions and alloimmunization risks, but also increased frequency of iron overload, a more significant problem in low-risk heavily transfused MDS patients, who have prolonged life expectancy. The use of growth factors is becoming a more and more important part of current supportive care. High-dose erythropoietin is able to reduce or suppress red blood cell transfusions needs in selected subgroups of MDS. The short-term use of granulocyte colony-stimulating factor is also often proposed in infections, although not formally established by prospective trials. Although trials of growth factors with thrombopoeitic activity have been performed with interleukin 11 and are underway with thrombopoeitin, none of them are available for routine use.
authors: Service d'Hématologe Clinique, Hôpital Avicenne & Université Paris XIII, Bobigny, France. claude.gardin@avc.aphp.fr
authors: Claude
authors: C
authors: Gardin
authors: Pierre
authors: P
authors: Fenaux
mesh_terms: D000740:Anemia / Q000209:etiology / Q000628:therapy; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D009503:Neutropenia / Q000209:etiology / Q000628:therapy; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy
chemical_list: D006133:Growth Substances; D011994:Recombinant Proteins; D004921:Erythropoietin